Abstract
No public abstract is available from the verified source records.
Niven Mehra, Andrew J. Armstrong, Mototsugu Oya, Neal Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Emma Brown, Jae Young Joung, Young Deuk Choi, Daniel Castellano, Yüksel Ürün, Christian Hosius, David McGuinness, Arnold Degboe
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
10.1038/s41391-018-0121-2 · 2019
Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer from the PREVAIL trial
10.1016/j.eururo.2020.04.061 · 2020
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
10.1016/s1470-2045(14)71205-7 · 2015
Unresolved referenced work
Kept as external metadata until matched
Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors
10.1007/s12325-021-01823-6 · 2021
Abiraterone and olaparib for metastatic castration-resistant prostate cancer
10.1056/evidoa2200043 · 2022
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
10.1016/s1470-2045(23)00382-0 · 2023
Unresolved referenced work
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
10.1016/s0090-4295(97)00459-7 · 1997
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation
10.1186/1477-7525-1-79 · 2003
Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer
10.1111/j.1524-4733.2008.00409.x · 2009
Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial
10.1200/jco.2023.41.16_suppl.5012 · 2023
Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the Phase 3 PROpel trial
10.1016/j.euo.2024.03.006 · 2024
Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
10.1200/jco.22.01649 · 2023
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)01055-3 · 2023
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
10.1016/s0140-6736(25)00684-1 · 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
10.1016/s0140-6736(25)00683-x · 2025
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
10.1038/s41591-023-02704-x · 2024
No additional external references are available.